Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2019

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2019

  • 200 Pages | 26-Jan-19 | Format:PDF | Last Updated: 26-Jan-19
  • GervanoRA’s Market Estimation report “Cannabidiol (CBD): Pipeline Analysis and Opportunity Assessment, H2 2018” analyzed the current and upcoming opportunities in the Cannabidiol (CBD) area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cannabidiol (CBD) industry. The report has been divided into segments like Cannabis Drug Overview, Market Overview and Pipeline Analysis to provide in depth insights about the market dynamics and ongoing R&D in the Cannabidiol (CBD) area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action, Pipeline Molecules by Stage of development, Pipeline Molecules by Indication, Pipeline Molecules by Source of Origin (Plant Derived versus Synthetic Analytics), Pipeline Molecules by Type (Cannabidiol –CBD v/s Tetrahydrocannabinol- THC). We have also analyzed the opportunities by area of application like the Pharmaceutical industry, Cosmetic industry and Food industry with their expected market values in 11 Major markets.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline Molecules
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. REPORT SUMMARY
    2.2. KEY EVENTS IN CANNABINOIDS COMPETITIVE SPACE
    2.3. KEY MAJOR FINDINGS
    2.3.1. DRIVERS
    2.3.2. RESTRAINTS
    2.3.3. UNMET NEEDS AND OPPORTUNITIES
    3. CANNABINOIDS DRUGS OVERVIEW
    3.1. CANNABIS OUTLOOK
    3.2. GLOBAL CANNABIS PRODUCT OUTLINE
    4. MARKET DYNAMICS
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.2.1. ACQUISITIONS
    4.2.2. COLLABORATION AGREEMENTS
    4.2.3. LICENSING AGREEMENTS
    4.2.4. TERMINATION AGREEMENTS AND SETTLEMENTS
    4.2.5. PARTNERSHIPS
    4.2.6. AGREEMENTS
    4.3. NEW DRUG APPROVALS (EMA)
    4.4. NEW DRUG APPROVALS (USFDA)
    4.5. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.1.7. HSD-UNKNOWN
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.6. PIPELINE ANALYSIS BY INDICATION
    5.6.1. UNMET NEEDS AND OPPORTUNITIES
    5.7. ANALYTICS ON PIPELINE MOLECULES BY SOURCE OF ORIGIN (PLANT DERIVED VERSUS SYNTHETIC ANALYTICS)
    5.8. ANALYTICS ON PIPELINE MOLECULES BY TYPE (CANNABIDIOL – CBD VS TETRAHYDROCANNABINOL -THC)
    5.9. ESTIMATED APPROVAL TIMELINES
    5.9.1. METHODOLOGY
    5.9.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    6. CANNABINOIDS OPPORTUNITIES BY AREA OF APPLICATION
    6.1. PHARMACEUTICAL INDUSTRY
    6.1.1. UNMET NEEDS AND OPPORTUNITIES
    6.1.2. EXPECTED MARKET IN 11MM
    6.2. FOOD INDUSTRY
    6.2.1. UNMET NEEDS AND OPPORTUNITIES
    6.2.2. EXPECTED MARKET IN 11MM
    6.3. COSMETIC INDUSTRY
    6.3.1. UNMET NEEDS AND OPPORTUNITIES
    6.3.2. EXPECTED MARKET IN 11MM
    7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    7.1. COMPANIES
    7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    7.1.1.1. GW RESEARCH LTD
    7.1.1.2. ABBVIE INC
    7.1.1.3. INSYS THERAPEUTICS
    7.1.1.4. MYLAN PHARMA
    7.1.1.5. TILRAY
    7.1.1.6. CANOPY GROWTH
    7.1.1.7. AURORA CANNABIS
    7.1.1.8. GREEN THUMB INDUSTRIES
    7.1.1.9. CRONOS GROUP
    7.1.2. EMERGING COMPANIES WITH COMPETITIVE OPPORTUNITIES
    7.1.2.1. KALYTERA THERAPEUTICS
    7.1.2.2. BOTANIX PHARMACEUTICALS
    7.1.2.3. PHYTECS
    7.1.2.4. CV SCIENCES, INC
    7.1.2.5. SERINA THERAPEUTICS, INC
    7.1.2.6. INTEC PHARMA LTD
    7.1.2.7. AXIM BIOTECHNOLOGIES
    7.1.2.8. INMED PHARMACEUTICALS INC
    7.1.2.9. CARA THERAPEUTICS (COVERED CANNABINOID RELATED INFORMATION ONLY)
    7.1.2.10. VIVACELL BIOTECHNOLOGY ESPANA SL
    7.1.2.11. CARDIOL THERAPEUTICS INC
    7.1.2.12. PIVOT PHARMACEUTICALS
    7.1.2.13. ARTELO BIOSCIENCES
    7.1.2.14. TETRA BIO-PHARMA
    7.1.2.15. NEMUS BIOSCIENCE INC
    7.1.2.16. SCYTHIAN BIOSCIENCES
    7.1.2.17. ICD PHARMA
    7.1.2.18. CANADIAN CANNABIS MEDICAL TECHNOLOGIES
    7.1.2.19. ZYNERBA PHARMACEUTICALS
    7.1.2.20. THERAPIX BIOSCIENCES
    7.1.2.21. REVIVE THERAPEUTICS
    7.1.2.22. PANAG PHARMA
    7.1.2.23. ZELDA THERAPEUTICS PTY LTD
    7.2. UNIVERSITIES AND INSTITUTES
    8. ABBREVIATIONS

    LIST OF TABLES

    TABLE 1: ECS STIMULATION ON DIFFERENT PARTS OF THE BODY
    TABLE 2: AMOUNT SPENT ON MARIJUANA REASERCH, 2014-2017, US, IN $M
    TABLE 3: MAJOR COLLABORATIVE AGREEMENTS INVOLVING CANNABINOID
    TABLE 4: MAJOR LICENSING AGREEMENTS INVOLVING CANNABINOID
    TABLE 5: MAJOR PARTNERSHIPS INVOLVING CANNABINOID
    TABLE 6: MAJOR AGREEMENTS INVOLVING CANNABINOID
    TABLE 7: EMA APPROVED CANNABIS DRUGS
    TABLE 8: US FDA APPROVED CANNABIS DRUGS
    TABLE 9: PHASE 3 MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 10: PHASE 2 MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 11: PHASE 1 MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 12: PRECLINICAL MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 13: EARLY R&D MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 14: HSD-UNKNOWN MOLECULES IN THE CANNABINOID DRUG PIPELINE
    TABLE 15: CANNABINOID DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 16: CANNABINOID DRUG PIPELINE MOLECULES BY TOPICAL AS ROUTE OF ADMINISTRATION
    TABLE17: CANNABINOID DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
    TABLE 18: CANNABIDIOL DRUG PIPELINE MOLECULES BY TRANSDERMAL AS ROUTE OF ADMINISTRATION
    TABLE 19: OTHER DIFFERENT ROUTE OF ADMINISTRATION FOR CANNABINOID DRUG PIPELINE
    TABLE 20: CANNABINOID DRUG PIPELINE INDICATED FOR CANCER
    TABLE 21: CANNABINOID DRUG PIPELINE INDICATED FOR CARDIOVASCULAR, METABOLICS & HEMATOLOGY
    TABLE 22: CANNABINOIDDRUG PIPELINE INDICATED FOR CENTRAL NERVOUS SYSTEM
    TABLE 23: CANNABINOID DRUG PIPELINE INDICATED FOR DERMATOLOGY
    TABLE 24: CANNABINOID DRUG PIPELINE INDICATED FOR ENT & OPHTHALMOLOGY MARKET
    TABLE 25: CANNABINOIDDRUG PIPELINE INDICATED FOR GASTROINTESTINAL MARKET
    TABLE 26: CANNABINOID DRUG PIPELINE INDICATED FOR GENETIC AND RARE DISEASE MARKET
    TABLE 27: CANNABINOID DRUG PIPELINE INDICATED FOR IMMUNOLOGY & INFLAMMATORY MARKET
    TABLE 28: CANNABINOID DRUG PIPELINE INDICATED FOR INFECTIOUS DISEASE MARKET
    TABLE 29: CANNABINOID DRUG PIPELINE INDICATED FOR RESPIRATORY MARKET
    TABLE 30: CANNABINOID DRUG PIPELINE MOLECULES IN OTHER MARKET
    TABLE 31: COMPANIES DEVELOPING PLANT DERIVED MOLECULES
    TABLE 32: COMPANIES DEVELOPING SYNTHETIC MOLECULES
    TABLE 33: COMPANIES DEVELOPING BIOSYNTHETIC MOLECULES
    TABLE 34: COMPANIES DEVELOPING CBD MOLECULES
    TABLE 35: COMPANIES DEVELOPING THC MOLECULES
    TABLE 36: COMPANIES DEVELOPING CBD AND THC MOLECULES
    TABLE 37: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 38: GW RESEARCH PRODUCT PORTFOLIO
    TABLE 39: R&D ACTIVITIES OF GW RESEARCH
    TABLE 40: CONFERENCES/SEMINARS ATTENDED BY GW RESEARCH
    TABLE 41: RECENT DEVELOPMENTS MADE BY GW RESEARCH
    TABLE 42: SWOT ANALYSIS OF GW RESEARCH
    TABLE 43: ABBVIE PRODUCT PORTFOLIO
    TABLE 44: CONFERENCES/SEMINARS ATTENDED BY ABBVIE
    TABLE 45: RECENT DEVELOPMENTS MADE BY ABBVIE
    TABLE 46: SWOT ANALYSIS OF ABBVIE
    TABLE 47: INSYS THERAPEUTICS PRODUCT PORTFOLIO
    TABLE 48: R&D ACTIVITIES OF INSYS THERAPEUTICS
    TABLE 49: CONFERENCES/SEMINARS ATTENDED BY INSYS THERAPEUTICS
    TABLE 50: RECENT DEVELOPMENTS MADE BY INSYS THERAPEUTICS
    TABLE 51: SWOT ANALYSIS OF INSYS THERAPEUTICS
    TABLE 52: MYLAN PHARMA PRODUCT PORTFOLIO
    TABLE 53: MYLAN PHARMA PRODUCT PIPELINE
    TABLE 54: CONFERENCES/SEMINARS ATTENDED BY MYLAN PHARMA
    TABLE 55: RECENT DEVELOPMENTS MADE BY MYLAN PHARMA
    TABLE 56: SWOT ANALYSIS OF MYLAN PHARMA
    TABLE 57: TILRAY PRODUCT PORTFOLIO
    TABLE 58: CONFERENCES/SEMINARS ATTENDED BY TILRAY
    TABLE 59: RECENT DEVELOPMENTS MADE BY TILRAY
    TABLE 60: SWOT ANALYSIS OF TILRAY
    TABLE 61: CANOPY GROWTH PRODUCT PORTFOLIO
    TABLE 62: RECENT DEVELOPMENTS MADE BY CANOPY GROWTH
    TABLE 63: SWOT ANALYSIS OF CANOPY GROWTH
    TABLE 64: AURORA CANNABIS PRODUCT PORTFOLIO
    TABLE 65: R&D ACTIVITIES OF AURORA CANNABIS
    TABLE 66: RECENT DEVELOPMENTS MADE BY AURORA CANNABIS
    TABLE 67: SWOT ANALYSIS OF AURORA CANNABIS
    TABLE 68: GREEN THUMB INDUSTRIES PRODUCT PORTFOLIO
    TABLE 69: CONFERENCES/SEMINARS ATTENDED BY GREEN THUMB INDUSTRIES
    TABLE 70: RECENT DEVELOPMENTS MADE BY GREEN THUMB INDUSTRIES
    TABLE 71: SWOT ANALYSIS OF GREEN THUMB INDUSTRIES
    TABLE 72: CRONOS GROUP PRODUCT PORTFOLIO
    TABLE 73: R&D ACTIVITIES OF CRONOS GROUP
    TABLE 74: SWOT ANALYSIS OF CRONOS GROUP
    TABLE 75: KALYTERA THERAPEUTICS FUTURE MILESTONES
    TABLE 76: KALYTERA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 77: BOTANIX PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 78: PHYTECS PRODUCT PORTFOLIO
    TABLE 79: PHYTECS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 80: CV SCIENCES FUTURE MILESTONES
    TABLE 81: CV SCIENCES RECENT DEVELOPMENTS AND MILESTONES
    TABLE 82: SERINA THERAPEUTICSRECENT DEVELOPMENTS AND MILESTONES
    TABLE 83: INTEC PHARMA FUTURE MILESTONES
    TABLE 84: INTEC PHARMA RECENT DEVELOPMENTS AND MILESTONES
    TABLE 85: AXIM BIOTECHNOLOGIES RECENT DEVELOPMENTS AND MILESTONES
    TABLE 86: INMED PHARMACEUTICALS FUTURE MILESTONES
    TABLE 87: INMED PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 88: VIVACELL BIOTECHNOLOGY RECENT DEVELOPMENTS AND MILESTONES
    TABLE 89: CARDIOL THERAPEUTICS FUTURE MILESTONES
    TABLE 90: CARDIOL THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 91: ARTELO BIOSCIENCES PRODUCT PORTFOLIO
    TABLE 92: RECENT DEVELOPMENTS AND FUTURE MILESTONES OF ARTELO BIOSCIENCES
    TABLE 93: TETRA BIO-PHARMA FUTURE MILESTONES
    TABLE 94: TETRA BIO-PHARMA RECENT DEVELOPMENTS AND MILESTONES
    TABLE 95: NEMUS BIOSCIENCE RECENT DEVELOPMENTS AND MILESTONES
    TABLE 96: ZYNERBA PHARMACEUTICALS FUTURE MILESTONES
    TABLE 97: ZYNERBA PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 98: ZELDA THERAPEUTICS FUTURE MILESTONES
    TABLE 99: ZELDA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
    TABLE 100: UNIVERSITIES AND INSTITUTES CONDUCTING RESEARCH ON CANNABINOIDS

    LIST OF FIGURES

    FIGURE 1: KEY PIPELINE EVENTS, 2019-2032
    FIGURE 2: KEY PIPELINE EVENTS, 2019-2021
    FIGURE 3: PHARMACODYNAMIC EFFECTS OF KEY CANNABINOIDS
    FIGURE 4: OVERALL DEALS ACTIVITY INVOLVING CANNABINOID
    FIGURE 5: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 6: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 7: CANNABINOID DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 8: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
    FIGURE 9: CANNABINOID DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 10: CANNABINOID DRUG PIPELINE ANALYSIS BY INDICATION
    FIGURE 11: GRAPHICAL VIEW OF PIPELINE MOLECULE’S STAGE OF DEVELOPMENT VS SOURCE OF ORIGIN
    FIGURE 12: GRAPHICAL VIEW OF PIPELINE MOLECULE’S GEOGRAPHY VS SOURCE OF ORIGIN
    FIGURE 13: PIPELINE MOLECULE’S ANALYTICS BY TYPE (CBD VS THC)
    FIGURE 14: GRAPHICAL VIEW OF PIPELINE MOLECULE’S STAGE OF DEVELOPMENT VS MOLECULE TYPE
    FIGURE 15: GRAPHICAL VIEW OF PIPELINE MOLECULE’S GEOGRAPHY VS MOLECULE TYPE
    FIGURE 16: CANNABINOID OPPORTUNITY ASSESSMENT
    FIGURE 17: TOTAL CANNABINOID MARKET, 2016 V/S 2025
    FIGURE 18: PHARMACEUTICAL INDUSTRY CANNABINOID MARKET, 2016 V/S 2025
    FIGURE 19: FOOD INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
    FIGURE 20: COSMETIC INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
    FIGURE 21: FINANCIAL INFORMATION OF GW RESEARCH
    FIGURE 22: FINANCIAL INFORMATION OF ABBVIE
    FIGURE 23: FINANCIAL INFORMATION OF INSYS THERAPEUTICS
    FIGURE 24: FINANCIAL INFORMATION OF MYLAN PHARMA
    FIGURE 25: FINANCIAL INFORMATION OF TILRAY
    FIGURE 26: FINANCIAL INFORMATION OF CANOPY GROWTH
    FIGURE 27: FINANCIAL INFORMATION OF AURORA CANNABIS
    FIGURE 28: FINANCIAL INFORMATION OF GREEN THUMB INDUSTRIES
    FIGURE 29: FINANCIAL INFORMATION OF CRONOS GROUP

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)